Hiramoto R N, Ghanta V K, Durant J R, Hiramoto N S
Cancer Clin Trials. 1980;3(4):395-402.
The basic problem of current animal models is the inability to select and rate the relative effectiveness of new drugs of myeloma of man. As a first step in broaching this problem, results of clinical drug trial studies were used for predicting activity of the drugs in the MOPC 104E plasmacytoma model. Comparison of the model with human myeloma and six additional murine plasmacytomas for drug response indicates close correlation between the reported results in man and the expected results in the animal models. The MOPC 104E model was versatile because drug effects could be rapidly measured in vivo in individual animals. The effect of the drug on the rate of growth, the rate of regression, the doubling time, the number of tumor cells killed, and the tumor and drug toxicities on the host could be continuously measured. These measurements were used to select active drugs and to rate the relative activity of the different drugs for myeloma.
当前动物模型的基本问题在于无法选择和评估针对人类骨髓瘤的新药的相对有效性。作为解决这一问题的第一步，临床药物试验研究的结果被用于预测药物在MOPC 104E浆细胞瘤模型中的活性。将该模型与人类骨髓瘤以及另外六种小鼠浆细胞瘤的药物反应进行比较，结果表明人类报告的结果与动物模型中的预期结果密切相关。MOPC 104E模型具有通用性，因为可以在个体动物体内快速测量药物效果。可以持续测量药物对生长速率、消退速率、倍增时间、杀死的肿瘤细胞数量以及肿瘤和药物对宿主的毒性的影响。这些测量结果被用于选择活性药物并评估不同药物对骨髓瘤的相对活性。
